89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Status Recruiting

Clinical Trial Summary

Bevacizumab can be an effective treatment for individuals with NF2 and improve different nerve functions (like hearing, tinnitus or balance problems) and the quality of life of NF2 patients. However, bevacizumab is not effective in all patients or all tumors, at the cost of moderate toxicity and considerable financial burden. Therefore, this observational study will validate an imaging biomarker method to predict bevacizumab efficacy in order to avoid adverse effects and high costs in non-responders to bevacizumab treatment. Patients will undergo standard-of-care treatment with the sole addition of a pre-treatment 89Zr-Bevacizumab PET/CT-scan. Per standard-of-care bevacizumab therapy is administered every three weeks for six months. To monitor treatment effect, follow-up is performed at 3-month intervals.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05685836
Study type	Observational
Source	Leiden University Medical Center
Contact	Jules PJ Douwes, MD
Phone	715269111
Email	j.p.j.douwes@lumc.nl
Status	Recruiting
Phase
Start date	October 20, 2022
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03617276` - Reliability of Functional Outcome Measures in Neurofibromatosis 2
Active, not recruiting	`NCT00973739` - Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors	Phase 2
Completed	`NCT00030043` - An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors	Phase 1
Completed	`NCT00004437` - Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2	Phase 2
Recruiting	`NCT03406208` - Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing	N/A
Active, not recruiting	`NCT03095248` - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors	Phase 2
Completed	`NCT02298270` - Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype	N/A
Recruiting	`NCT01885767` - Neurofibromatosis (NF) Registry Portal
Completed	`NCT00863122` - Concentration and Activity of Lapatinib in Vestibular Schwannomas	Early Phase 1
Recruiting	`NCT03079999` - Study of Aspirin in Patients With Vestibular Schwannoma	Phase 2
Terminated	`NCT00911248` - PTC299 for Treatment of Neurofibromatosis Type 2	Phase 2
Completed	`NCT02811718` - Resiliency Training for Patients With NF2 Via Videoconferencing With Skype	N/A
Enrolling by invitation	`NCT04890132` - Vestibular Precision: Physiology & Pathophysiology	N/A
Completed	`NCT01490476` - Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients	Phase 2
Active, not recruiting	`NCT00004483` - NF2 Natural History Consortium	N/A
Recruiting	`NCT03893643` - Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
Active, not recruiting	`NCT04283669` - Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas	Phase 2
Completed	`NCT02831257` - AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas	Phase 2